These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21437987)

  • 61. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.
    Olanow CW; Schapira AH; LeWitt PA; Kieburtz K; Sauer D; Olivieri G; Pohlmann H; Hubble J
    Lancet Neurol; 2006 Dec; 5(12):1013-20. PubMed ID: 17110281
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Which dyskinesia scale best detects treatment response?
    Goetz CG; Stebbins GT; Chung KA; Hauser RA; Miyasaki JM; Nicholas AP; Poewe W; Seppi K; Rascol O; Stacy MA; Nutt JG; Tanner CM; Urkowitz A; Jaglin JA; Ge S
    Mov Disord; 2013 Mar; 28(3):341-6. PubMed ID: 23390076
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
    Poewe W; Hauser RA; Lang A;
    Mov Disord; 2015 Apr; 30(4):589-92. PubMed ID: 25545629
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS.
    Horváth K; Aschermann Z; Ács P; Deli G; Janszky J; Komoly S; Balázs É; Takács K; Karádi K; Kovács N
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1421-6. PubMed ID: 26578041
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intensive rehabilitation treatment in early Parkinson's disease: a randomized pilot study with a 2-year follow-up.
    Frazzitta G; Maestri R; Bertotti G; Riboldazzi G; Boveri N; Perini M; Uccellini D; Turla M; Comi C; Pezzoli G; Ghilardi MF
    Neurorehabil Neural Repair; 2015 Feb; 29(2):123-31. PubMed ID: 25038064
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.
    Yoritaka A; Takanashi M; Hirayama M; Nakahara T; Ohta S; Hattori N
    Mov Disord; 2013 Jun; 28(6):836-9. PubMed ID: 23400965
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Minimal clinically important change on the Headache Impact Test-6 questionnaire in patients with chronic tension-type headache.
    Castien RF; Blankenstein AH; Windt DA; Dekker J
    Cephalalgia; 2012 Jul; 32(9):710-4. PubMed ID: 22707519
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease.
    Lim TT; Kluger BM; Rodriguez RL; Malaty IA; Palacio R; Ojo OO; Patel S; Gujrati Y; Nutter B; Swartz C; Hennessy C; Fernandez HH
    Mov Disord; 2015 Nov; 30(13):1825-30. PubMed ID: 26769459
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations.
    Tsang KL; Ho SL; Lo SK
    Neurology; 2000 Jun; 54(12):2292-8. PubMed ID: 10881255
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.
    Hattori N; Takeda A; Takeda S; Nishimura A; Kitagawa T; Mochizuki H; Nagai M; Takahashi R
    J Neural Transm (Vienna); 2019 Mar; 126(3):299-308. PubMed ID: 30689042
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study.
    Im JJ; Jeong H; Chung YA; Park JS; Heo Y; Oh JK; Song IU
    J Neuroimaging; 2019 Nov; 29(6):707-711. PubMed ID: 31463990
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Responsiveness and minimal clinically important change of the Pain Disability Index in patients with chronic back pain.
    Soer R; Reneman MF; Vroomen PC; Stegeman P; Coppes MH
    Spine (Phila Pa 1976); 2012 Apr; 37(8):711-5. PubMed ID: 21796022
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease.
    Goetz CG; Leurgans S; Raman R;
    Mov Disord; 2002 Mar; 17(2):283-8. PubMed ID: 11921113
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Trial of Lixisenatide in Early Parkinson's Disease.
    Meissner WG; Remy P; Giordana C; Maltête D; Derkinderen P; Houéto JL; Anheim M; Benatru I; Boraud T; Brefel-Courbon C; Carrière N; Catala H; Colin O; Corvol JC; Damier P; Dellapina E; Devos D; Drapier S; Fabbri M; Ferrier V; Foubert-Samier A; Frismand-Kryloff S; Georget A; Germain C; Grimaldi S; Hardy C; Hopes L; Krystkowiak P; Laurens B; Lefaucheur R; Mariani LL; Marques A; Marse C; Ory-Magne F; Rigalleau V; Salhi H; Saubion A; Stott SRW; Thalamas C; Thiriez C; Tir M; Wyse RK; Benard A; Rascol O;
    N Engl J Med; 2024 Apr; 390(13):1176-1185. PubMed ID: 38598572
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia.
    Pahwa R; Fox S; Hauser RA; Isaacson S; Lytle J; Johnson R; Llorens L; Formella AE; Tanner CM
    Front Neurol; 2022; 13():846126. PubMed ID: 36341088
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.
    Chang Y; Wang LB; Li D; Lei K; Liu SY
    Ann Med; 2017 Aug; 49(5):421-434. PubMed ID: 28293967
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.
    Barone P; Santangelo G; Morgante L; Onofrj M; Meco G; Abbruzzese G; Bonuccelli U; Cossu G; Pezzoli G; Stanzione P; Lopiano L; Antonini A; Tinazzi M
    Eur J Neurol; 2015 Aug; 22(8):1184-91. PubMed ID: 25962410
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].
    Levin OS; Boĭko AN; Ivanov AK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 2):42-7. PubMed ID: 21389939
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adjunct rasagiline to treat Parkinson's disease with motor fluctuations: a randomized, double-blind study in China.
    Zhang Z; Shao M; Chen S; Liu C; Peng R; Li Y; Wang J; Zhu S; Qu Q; Zhang X; Chen H; Sun X; Wang Y; Sun S; Zhang B; Li J; Pan X; Zhao G
    Transl Neurodegener; 2018; 7():14. PubMed ID: 29988514
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.
    Hauser RA; Abler V; Eyal E; Eliaz RE
    Int J Neurosci; 2016 Oct; 126(10):942-6. PubMed ID: 26988747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.